BNTC - Benitec Biopharma Inc
IEX Last Trade
9.02
-0.030 -0.333%
Share volume: 12,373
Last Updated: Fri 30 Aug 2024 08:50:40 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$9.05
-0.03
-0.33%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-05-16 | 2022-09-02 | 2022-11-10 | 2023-02-13 | 2023-05-15 | 2023-09-21 | 2023-11-13 | 2024-02-13 | |
| Assets | |||||||||
| Total Assets | 10.064 M | 5.973 M | 18.115 M | 11.905 M | 8.220 M | 4.464 M | 27.053 M | 21.353 M | |
| Current Assets | 8.841 M | 4.820 M | 17.081 M | 10.975 M | 7.395 M | 3.729 M | 26.412 M | 20.796 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 206.000 K | 741.000 K | 531.000 K | 356.000 K | 774.000 K | 1.184 M | 482.000 K | 355.000 K | |
| Short Term Investments | 206.000 K | 741.000 K | 531.000 K | 356.000 K | 774.000 K | 1.184 M | 482.000 K | 355.000 K | |
| Total Receivables | 5.000 K | 3.000 K | 3.000 K | 68.000 K | 56.000 K | 55.000 K | 53.000 K | 53.000 K | |
| Current Cash | 8.630 M | 4.062 M | 16.534 M | 10.537 M | 6.551 M | 2.477 M | 25.864 M | 20.374 M | |
| Total Non-current Assets | 1.223 M | 1.153 M | 1.034 M | 930.000 K | 825.000 K | 735.000 K | 641.000 K | 557.000 K | |
| Property Plant Equipment | 214.000 K | 222.000 K | 179.000 K | 139.000 K | 106.000 K | 87.000 K | 68.000 K | 51.000 K | |
| Other Assets | 1.009 M | 931.000 K | 855.000 K | 791.000 K | 719.000 K | 648.000 K | 573.000 K | 506.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 10.064 M | 5.973 M | 18.115 M | 11.905 M | 8.220 M | 4.464 M | 27.053 M | 21.353 M | |
| Total liabilities | 2.544 M | 3.091 M | 3.502 M | 2.911 M | 3.507 M | 4.262 M | 4.745 M | 5.883 M | |
| Total current liabilities | 1.909 M | 2.532 M | 3.011 M | 2.489 M | 3.153 M | 3.978 M | 4.534 M | 5.746 M | |
| Accounts Payable | 1.320 M | 1.880 M | 2.368 M | 1.830 M | 2.455 M | 3.231 M | 3.794 M | 4.937 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 232.000 K | 252.000 K | 258.000 K | 263.000 K | 269.000 K | 275.000 K | 280.000 K | 286.000 K | |
| Long term debt | 635.000 K | 559.000 K | 491.000 K | 422.000 K | 354.000 K | 284.000 K | 211.000 K | 137.000 K | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 7.520 M | 2.882 M | 14.613 M | 8.994 M | 4.713 M | 202.000 K | 22.308 M | 15.470 M | |
| Common stock | 480.688 K | 480.688 K | 638.571 K | 1.621 M | 1.646 M | 1.637 M | 36.670 M | 43.798 M | |
| Retained earnings | -143.260 M | -148.327 M | -153.420 M | -158.831 M | -163.228 M | -167.889 M | -173.843 M | -180.641 M |